3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Lymphoid
3
Gastrointestinal
3
Plasma cell
2
Other hematologic neoplasm
2
Tumor-Agnostic
1
Sarcoma
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Genomic Instability
1
Interventions
Carboplatin
191
pembrolizumab
155
Pemetrexed
134
Cisplatin
117
durvalumab
71
Paclitaxel
71
osimertinib
67
Nivolumab
66
Docetaxel
63
Specimen Handling
61
atezolizumab
57
Magnetic Resonance Spectroscopy
50
Etoposide
46
Gemcitabine
42
Radiotherapy
39
Radiosurgery
37
130-nm albumin-bound paclitaxel
34
Drug Therapy
30
Cetuximab
28
Bevacizumab
27
Ipilimumab
25
Taxes
23
cemiplimab
22
tislelizumab
20
Platinum
20
amivantamab
18
Radiation
18
Immunoglobulin G
17
1,2-diaminocyclohexaneplatinum II citrate
17
Disulfides
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Vemurafenib
×
Thoracic
×
90 days
×
Clear all
NCT03178552
2026-06-05
B-FAST
Hoffmann-La Roche
Phase 2/3
Active not recruiting
1,000 enrolled
NCT04302025
2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2
Recruiting
99 enrolled
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled